Processa pharmaceuticals issues letter to shareholders highlighting corporate strategy, drug pipeline, and outlook

Hanover, md, nov. 29, 2023 (globe newswire) -- processa pharmaceuticals, inc. (nasdaq: pcsa) (“processa” or the “company”), a clinical-stage pharmaceutical company now focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from cancer, announces that ceo george ng has issued a letter to shareholders.
PCSA Ratings Summary
PCSA Quant Ranking